Winston & Strawn LLP is serving as underwriters counsel to R.F. Lafferty in connection with Cuprina Holdings, a biomedical and biotechnology company dedicated to the development and commercialization of products for chronic wound management and cosmeceuticals, in its announced closing of a $12 million initial public offering. The offering consisted of 3,000,000 ordinary shares at a public offering price of $4 per share, before deducting underwriting discounts and offering expenses.
Cuprina intends to use net proceeds from the offering for expansion into new markets, R&D activities to expand its product portfolio, building brand awareness, investment in equipment and infrastructure, and working capital and general corporate purposes.
In separate IPO news, Titan Acquisition Corp (Nasdaq: TACHU) announced the closing of its initial public offering of 27,600,000 units at $10.00 per unit, including 3,600,000 units from the underwriters’ full exercise of their over-allotment option. The blank check company raised gross proceeds of $276 million before deducting underwriting discounts and estimated offering expenses.
Each Titan unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder to purchase one Class A ordinary share at $11.50 per share. The units began trading on the Nasdaq Global Market under the ticker symbol “TACHU” on April 9, 2025. Once separated, the Class A ordinary shares and warrants are expected to trade under the symbols “TACH” and “TACHW,” respectively.
Cantor Fitzgerald & Co. acted as the sole book-running manager for the Titan offering, with Odeon Capital Group LLC serving as co-manager.
